You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)向和記黃埔中國出售消費產品業務權益
和黃醫藥(00013.HK)宣布,為專注核心業務範疇,全資附屬公司和黃醫藥集團投資將向長和(00001.HK)間接附屬和記黃埔中國出售消費產品業務權益,分別為和黃漢優有機 50%股權及和黃醫藥營養全部股權,總代價為3,980萬元(折合約510萬美元),預期將錄得出售收益約10萬美元,所得款項用於其發現、全球開發和商業化治療癌症和免疫性疾病之靶向藥物和免疫療法之核心業務。 目前Hutchison Healthcare Holdings Limited持有和黃醫藥約38.16%股份,而和記黃埔中國為Hutchison Healthcare Holdings Limited的控股公司,因此和記黃埔中國為該公司的關連人士。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account